4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4/A - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4/A - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

10-Q - Ernexa Therapeutics Inc. (0000748592) (Filer)

10-Q - Ernexa Therapeutics Inc. (0000748592) (Filer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

EFFECT - Ernexa Therapeutics Inc. (0000748592) (Filer)

424B3 - Ernexa Therapeutics Inc. (0000748592) (Filer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

SCHEDULE 13D/A - Ernexa Therapeutics Inc. (0000748592) (Subject)

S-8 - Ernexa Therapeutics Inc. (0000748592) (Filer)

S-3 - Ernexa Therapeutics Inc. (0000748592) (Filer)

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the presentation of new preclinical data on its lead cell therapy candidate, ERNA-101, at the American Society of Hematology (ASH) Annual Meeting. The data demonstrated that its proprietary cell therapy platform can rapidly and durably reprogram immunosuppressive tumor microenvironments (TMEs) into immune-active, pro-inflammatory states to combat cancer. The platform engineers induced pluripotent stem cells (iPSCs) and transforms them into induced mesenchymal stem cells (iMS

CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that data from its novel cell therapy platform will be shared in an oral presentation at the 67th ASH Annual Meeting, being held December 6-9, 2025 in Orlando, FL. "Being selected to give an oral presentation at ASH is a tremendous honor and a major milestone," said Sanjeev Luther, President & CEO of Ernexa Therapeutics. "It's a recognition of the potential of our iMSC platform to transform the tumor microenvironment and drive a targeted immune response. We're proud to share

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board. Dr. Winer is a nationally recognized gynecologic oncologist and translational scientist. His expertise in women's oncology, immunotherapy, and early-phase clinical development further strengthens Ernexa's capabilities as it advances its proprietary induced mesenchymal stem cells (iMSC) platform and lead program, ERNA-101, toward key milestones, including first-in-human tria

CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will present at Cell 2025, Oxford Global's premier event, being held on November 11 and 12, 2025 in London, UK. Details of the presentations are as follows: Title: Preparing Cell Therapies for ClinicsPresenter: Sanjeev Luther, President and CEO of Ernexa TherapeuticsSession: Innovation and Collaboration ProgrammeDate and Time: Wednesday, November 12th at 12:50 PM GMTLocation: Conference Room 4: Muscadet, Novotel London West, London, UK Panel Presentation: Challenges of

The Company's operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1 study in platinum-resistant ovarian cancer (PROC), anticipated in H2 2026 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its financial results for the three- and nine-month periods ended September 30, 2025, and highlighted its continued operational execution. Recent Highlights Announced a cel

Access the "What This Means" segment here CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor "What This Means" segment. As part of the segment, Sanjeev Luther, President and CEO of Ernexa, discussed the Company's recently announced partnership agreement with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa's lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinic

In the news release, Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer, issued Oct. 29, 2025 by Cellipont Bioservices over PR Newswire, we are advised by the company that the logo has been updated. The complete press release that includes the updated logo follows: Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer THE WOODLANDS, Texas, and CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO)

THE WOODLANDS, Texas, and CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced it has entered into a collaboration with Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease. The partnership agreement will focus on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa's lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its upcoming company presentation at the Cell & Gene Meeting on the Mesa, taking place on October 7 in Phoenix, Arizona, and virtually online. "We are honored to participate in the Cell & Gene Meeting on the Mesa, one of the most important gatherings for advancing cell and gene therapies," said Sanjeev Luther, President and CEO of Ernexa Therapeutics. "This presentation is an opportunity to highlight Ernexa's progress in developing scalable, iMSC therapies for cancer and autoimmune disease,

CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjeev Luther, will participate in a featured panel discussion at the upcoming 5th Annual iPSC Drug Development Summit on October 1 in Boston. "Participation in the iPSC Drug Development Summit provides Ernexa the opportunity to contribute to important conversations shaping the future of cell therapy," said Luther. "We believe our synthetic iMSC approach has the potential to overcome key barriers in the field and ultimately deliver scalable, transformative th

The Company's operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1 study in platinum-resistant ovarian cancer (PROC), anticipated in H2 2026 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its financial results for the three- and nine-month periods ended September 30, 2025, and highlighted its continued operational execution. Recent Highlights Announced a cel

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) --  Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution of a securities purchase agreement with accredited investors for the sale of approximately $9.2 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase an aggregate of 9,579,014 shares of common stock in a private placement transaction that was priced at-the-market under Nasdaq rules. The Company expects to hold an initial closing at which it exp

CAMBRIDGE, MASS., July 18, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution and closing of the sale of approximately $8.7 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase common stock in a private placement transaction that closed on July 14, 2023 and was priced at-the-market under Nasdaq rules. The notes, which were issued at par, bear interest at a rate of 6.0% per year, payable quarterly, and mature in July 2028

Acquisition includes Exacis' entire pipeline of engineered cell therapy programs for hematologic and solid tumors CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics ("Exacis"). The acquisition complements Eterna's core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna with an exclusive g

– Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited induced pluripotent stem cell (iPSC)-derived therapies for multiple neurology indications – Entered into a sublease agreement with Bristol Myers Squibb to occupy 45,000 sq. ft. of lab and office space at Cambridge Crossing development in Cambridge, Massachusetts – Appointed Matt Angel, Ph.D. as Chief Executive Officer and President CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicine

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board. Dr. Winer is a nationally recognized gynecologic oncologist and translational scientist. His expertise in women's oncology, immunotherapy, and early-phase clinical development further strengthens Ernexa's capabilities as it advances its proprietary induced mesenchymal stem cells (iMSC) platform and lead program, ERNA-101, toward key milestones, including first-in-human tria

CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of Elena Ratner, M.D., M.B.A, to the Board of Directors. Dr. Ratner will spearhead the strategic direction of Eterna's efforts to combat ovarian cancer, leveraging her extensive expertise in obstetrics, gynecology, and reproductive sciences. Under her leadership, the company aims to accelerate advancements in innovative therapies targeting these high-priority areas in women's health. This direction is bolstered by Eterna's recent collaboration with MD Anderson Cancer Center. Announced last month, the p

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a preclinical-stage biopharmaceutical company, committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announces the appointment of Mahendra Rao, PhD, to its scientific advisory board. "We're honored to have Dr. Mahendra Rao join our Scientific Advisory Board," said Sanjeev Luther, President and CEO of Eterna. "His deep scientific expertise in regenerative medicine and cell engineering will be invaluable to our company in its upcoming phases of scientific and clinical development as we strive to brin

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Peter Cicala, JD, to its Board of Directors. "Peter Cicala has deep experience in the biotechnology and pharmaceutical industry, from start-ups to big pharma, and from bench to commercialization," said Sanjeev Luther, President and CEO of Eterna. "We are very pleased to have him join our Board to support value creation through the development of next-generation therapies using mRNA cell engineerin

CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024. Mr. Luther will replace Matt Angel, Ph.D., the current President and Chief Executive Officer. James Bristol, Ph.D., Chairman of Eterna's Board of Directors, said, "We are excited to have Sanjeev take on the role of President and CEO of Eterna as we continue our work to support the deve

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of James Bristol, Ph.D., to its Board of Directors. "Dr. Bristol is a seasoned biopharmaceutical executive who has excelled as a corporate partner, board member, and strategic and technical advisor within our industry," said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna. "We are thrilled to have him join our Board as we continue our mission of supporting the development of next-g

CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Dorothy Clarke to its Board of Directors. "We are delighted to welcome Dorothy to our Board," said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna. "Dorothy's extensive regulatory and legal expertise and experience as a Fortune 100 executive in the biopharmaceutical and healthcare sector will be invaluable as we continue to execute on our business and partnering strategies to

CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Brant Binder and Richard Wagner, Ph.D. to its Board of Directors. Concurrently, Charles Cherington and Nicholas Singer have stepped down from the Board. "We are delighted to welcome Brant and Richard to our Board. Both bring a wealth of industry expertise, including founding and leading biotechnology companies with a proven history of delivering value for their stakeholders," said Matt Angel, Ph.D

Renowned scientist and serial entrepreneur Jeff Karp, Ph.D., brings deep research experience and industry knowledge that will help guide Eterna as it advances its mRNA cell engineering platform CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Jeff Karp, Ph.D. to Eterna's Scientific Advisory Board. Matt Angel, Ph.D., Chief Executive Officer and President of Eterna, commented, "Jeff is a world-class expert in drug delivery and cell therapeutics